Search Results
Your search for ,maY matches 17054 pages
Showing 11901 - 11950Sixteen Leaders in Breast Cancer Research Join Susan G. Komen as Advisors
Susan G. Komen recently welcomed 16 leaders in breast cancer research and advocacy who will serve as Komen Scholars—an international advisory group that helps to guide Komen’s research and scientific programs, education and advocacy work, and public health efforts in the United States and abroad....
Chief Research Officer Named at the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network has announced Lynn Matrisian, PhD, MBA, as inaugural Chief Research Officer for the organization. Dr. Matrisian was promoted from Vice President of Scientific and Medical Affairs, where she has served since 2011. “To meet our aggressive goal to double survival...
Expert Point of View: Julie Margenthaler, MD and Mahmoud El-Tamer, MD
Press briefing moderator Julie Margenthaler, MD, of Washington University Siteman Cancer Center, St. Louis, who is Communications Committee Chair for the American Society of Breast Surgeons, agreed that surveillance would be acceptable only within a clinical trial, and one is underway now....
Recurrences Observed in More Than 50% of Inadequately Treated Patients With Ductal Carcinoma in Situ
A mid much debate about the potential for overly aggressive treatment of ductal carcinoma in situ comes a study that gives one pause. According to research presented at the 17th Annual Meeting of the American Society of Breast Surgeons, more than half of all women with ductal carcinoma in situ that ...
Sheldon M. Feldman, MD, Named President of ASBrS
Sheldon M. Feldman, MD, was named President of the American Society of Breast Surgeons (ASBrS) at the organization’s 2016 Annual Meeting in Dallas, Texas. Dr. Feldman is the Chief of Breast Surgery at NewYork-Presbyterian/Columbia University Medical Center and the Vivian L. Milstein Associate...
AUA 2016: Cell-Cycle Progression Score Provides Significant Prognostic Information in Patients With Gleason Score < 7
Myriad Genetics announced results from a study of the prognostic information provided by its Prolaris test in patients with prostate cancer and a Gleason score < 7 at the 111th Annual Scientific Meeting of the American Urological Association (AUA) (Abstract MP02-20). Prolaris is a novel 46-gene ...
ASH Meets With Officials, Provides Recommendations for the National Cancer Moonshot Initiative
On April 26, 2016, American Society of Hematology (ASH) President Charles S. Abrams, MD, shared the following statement: “Today ASH met with the White House to share scientific recommendations for the National Cancer Moonshot, an initiative spearheaded by Vice President Joe Biden that aims to make...
Tell Your Patients About PRE-ACT
Preparatory Education About Clinical Trials (PRE-ACT), a free video-based program, helps patients and their caregivers learn about clinical trials and address barriers to participation. Direct your patients to cancer.net/preact to learn more about this online resource. Also, visit cancer.net/blog...
Shop to Conquer Cancer!
ASCO Annual Meeting attendees have a special opportunity to support the Conquer Cancer Foundation (CCF) when you shop with any CCF retail partner during your stay in Chicago. When presented with the Conquer Cancer Card, participating retailers will donate a portion of sales from purchases made...
AUA 2016: BRCA Gene Mutations Associated With Increased Prostate Cancer Risk
Though predominantly known for their increased associations with breast cancer risk, germline mutations in the BRCA1 and BRCA2 genes are also associated with an increased susceptibility to other diseases, including prostate cancer. New data being presented during the 111th Annual Scientific Meeting ...
Redesigned ASCO.org Launches With Improved Usability
ASCO launched a new and improved website in early April, with a focus on improving the user experience. The Society’s redesigned online home makes it easier than ever for members and visitors to find the oncology-related information and resources they trust and value. The site’s redesign is the...
Interactive, Focused Learning at the ASCO Annual Meeting
The ASCO Annual Meeting, which will be held June 3–7, 2016, in Chicago, brings together more than 30,000 oncology professionals from around the world to learn about and discuss the latest therapies, treatment modalities, research, and controversies in the field. Attendees are able to personalize...
AUA 2016: Adjuvant Chemotherapy After Radical Prostatectomy May Benefit Men at High Risk for Relapse
Not all men with prostate cancer benefit from adjuvant chemotherapy after radical prostatectomy; however, African American men and men with a higher tumor stage may, according to a new U.S. Department of Veterans Affairs (VA) study (Abstract PI LBA 06) featured at the 111th Annual Scientific...
New JOP Articles Highlight the Impact of NCI Programs on Clinical Trial Enrollment
Two new original contributions in the Journal of Oncology Practice (JOP) highlight how National Cancer Institute (NCI) programs have impacted clinical trial enrollment. The first1 looked at the pilot phase of the NCI’s Community Cancer Centers Program (NCCCP) and found that trial availability and...
Donor Spotlight: Gateway for Cancer Research
The Conquer Cancer Foundation of ASCO is collaborating with Gateway for Cancer Research (Gateway) to fund a 2016 and 2017 Young Investigator Award through the Conquer Cancer Foundation Grants and Awards program. “Conquer Cancer Foundation is grateful for the generous support from Gateway and...
Defibrotide Sodium for Hepatic Veno-occlusive Disease After HSCT
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 30, 2016, defibrotide sodium (Defitelio) was approved for...
Shedding Light on a Cornucopia of Breast Tumor Biomarker Assays
As our understanding of the complexities of breast cancer expands, so does our treatment armamentarium—and along with it the range of factors that must be included in our treatment decisions. Gone is the simple algorithm of adjuvant chemotherapy for almost every patient with a ≥ 2-cm tumor, except...
ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer
As reported in the Journal of Clinical Oncology by Lyndsay N. Harris, MD, and colleagues,1 ASCO has released a clinical practice guideline on the use of biomarkers in addition to estrogen receptor/progesterone receptor and HER2 status to guide decisions on adjuvant systemic therapy in women with...
Moving Forward in Castration-Resistant Prostate Cancer: The TERRAIN and STRIVE Studies
It was over 2 decades ago that my colleagues and I reported in The New England Journal of Medicine that a first-generation oral antiandrogen, flutamide, when added to a luteinizing hormone–releasing hormone (LHRH) agonist, improved survival by nearly 6 months compared to an LHRH agonist alone in...
Enzalutamide Produces Large Progression-Free Survival Benefit vs Bicalutamide in Two Trials in Castration-Resistant Prostate Cancer
In the randomized phase II TERRAIN trial reported in The Lancet Oncology, Neal D. Shore, MD, of Carolina Urologic Research Center, Myrtle Beach, and colleagues found that use of the androgen receptor inhibitor enzalutamide (Xtandi) more than doubled median progression-free survival vs bicalutamide...
Breaking Down Dogma With the Outgoing President of SGO
At the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, The ASCO Post sat down with the SGO’s outgoing President, Robert L. Coleman, MD, and discussed the revolutionary potential of blood biomarkers, why enhanced recovery after surgery protocols is a significant...
Robert Weinberg, PhD, Receives AACR Award for Lifetime Achievement in Cancer Research
Robert Weinberg, PhD, was honored for his seminal contributions to cancer research and cancer biology with the 13th annual American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research at the 2016 AACR Annual Meeting, held in New Orleans, April 16–20. The AACR...
Waun Ki Hong, MD, Receives 10th AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) honored Waun Ki Hong, MD, with the 10th annual Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the 2016 AACR Annual Meeting, held in New Orleans, April 16–20. The Margaret Foti Award for Leadership and...
FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The capsule...
Roundup of Ovarian Cancer Abstracts From 2016 SGO Annual Meeting on Women’s Cancer
At the 2016 Society of Gynecologic Oncology’s (SOG’s) Annual Meeting on Women’s Cancer, Thomas J. Herzog, MD, Clinical Director, University of Cincinnati (UC) Cancer Institute and Professor of Obstetrics and Gynecology at UC College of Medicine, provided commentary on several noteworthy ovarian...
Expert Point of View: Gini Fleming, MD
In the discussion session, Gini Fleming, MD, Professor of Medicine and Director of the Gynecologic Oncology and Medical Oncology Breast Program at the University of Chicago Medical Center, analyzed the three previous, large trials on which the presumed benefits of intraperitoneal therapy in women...
Intraperitoneal Chemotherapy in Question in Ovarian Cancers
A phase III trial of bevacizumab (Avastin) with intravenous vs intraperitoneal chemotherapy showed no improvement in progression-free survival for first-line treatment of patients with optimally surgically resected stage II and III ovarian, peritoneal, or fallopian tube cancer.1 When compared with...
Selected Abstracts From the 2016 BMT Tandem Meetings
The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research and the American Society of Blood and Marrow Transplantation. Held recently in Honolulu, Hawaii, this year’s BMT Tandem Meetings drew 3,000 attendees from 35 countries,...
CancerCare Issues Report on Nationwide Surveys of 3,000 People Diagnosed With Cancer
The national nonprofit organization CancerCare has announced the publication of a comprehensive report on experiences, perceptions, and needs of people who are living with and beyond a cancer diagnosis. The 2016 CancerCare Patient Access and Engagement Report is a compilation of results from six...
Expert Point of View: Harold Burstein, MD, PhD
Invited discussant Harold Burstein, MD, PhD, Associate Professor of Medicine at Harvard Medical School and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women’s Hospital, Boston, called MINDACT “a heroic effort” whose results show that combining stage, pathology, and...
First Results From MINDACT Confirm the Benefit of Genomic Profiling
The primary analysis of the MINDACT trial confirms the value of genomic profiling for patients with early breast cancer with zero to three positive lymph nodes, according to MINDACT investigators and breast cancer specialists who heard the results at the 2016 American Association of Cancer Research ...
Expert Point of View: Mark Pegram, MD & Martine Piccart, MD, PhD
Formal discussant of the ado-trastuzumab emtansine plus pertuzumab trial, Mark Pegram, MD, Director of the Breast Cancer Program at Stanford Women’s Cancer Center and Co-Director of Stanford’s Molecular Therapeutics Program, Stanford, California, said that I-SPY 2 has several strengths. They...
Ado-Trastuzumab Emtansine Plus Pertuzumab: Promising Neoadjuvant Results for HER2-Positive Breast Cancer From the I-SPY 2 Trial
The combination of ado-trastuzumab emtansine (Kadcyla) plus pertuzumab (Perjeta) is a worthy combination to pursue in phase III studies as neoadjuvant therapy for HER2-positive invasive breast cancer, according to findings in the I-SPY 2 trial presented at the 2016 Annual Meeting of the American...
Expert Point of View: Lillian L. Siu, MD, FASCO
“This is an important study,” said formal discussant Lillian L. Siu, MD, FASCO, Professor, University of Toronto Cancer Care Ontario Research Chair and medical oncologist at Princess Margaret Cancer Centre Drug Development Program in Toronto, Ontario, Canada. “No new drugs have been approved by the ...
Nivolumab: New Standard of Care for Progressive Head and Neck Cancer After Platinum Therapy
Squamous cell carcinoma of the head and neck that progresses after platinum-based therapy has a dismal prognosis, and there is no effective standard of care. No treatment has improved survival for this patient population, but that may be about to change. Nivolumab (Opdivo), an anti–PD-1 (programmed ...
Dethroning the Emperor of All Maladies
Deep knowledge of immunology, cancer biology, and disruptive technology in computational science and molecular profiling has positioned us to dethrone the emperor of all maladies. The cancer research community is prepared to fulfill President Barack Obama’s call for a national cancer moonshot aimed ...
Using Telemedicine to Reduce Wait Times for Veterans
John Farrow, a 67-year-old Vietnam veteran, had not been able to sleep for days. A week ago, his primary care doctor at his local outpatient Veterans Administration (VA) clinic told him that his prostate-specific antigen (PSA) blood level was rapidly increasing, and his prostate was abnormal on...
Making the Moonshot Initiative a Reality
Excitement was high on the last day of the 2016 Annual Meeting of the American Association for Cancer Research (AACR) in anticipation of Vice President Joseph R. Biden’s remarks related to the Moonshot Initiative to accelerate progress in cancer research. The Secret Service made elaborate...
Expert Point of View: Jedd D. Wolchok, MD, PhD
“We are at a fortunate time to have multiple routes to ‘lifetime’ (T-cell) memory (including ipilimumab [Yervoy] and nivolumab [Opdivo]),” said Jedd D. Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, who was the formal discussant of the CA909-003 trial at the American...
One-Third of Patients With Advanced Melanoma Survive at Least 5 Years After Nivolumab Treatment
The news is good from the longest follow-up survival study of patients with advanced melanoma who were treated with the anti–programmed cell death protein 1 (PD-1) agent nivolumab (Opdivo).1 Thirty-four percent of patients who received the drug in a phase I trial (CA909-003) were alive 5 years...
Study Explores Differential Localization of Glioblastoma Subtypes and Pathogenesis
Researchers at the University of California San Diego School of Medicine have demonstrated that distinct types of glioblastoma tend to develop in different regions of the brain. This finding provides an explanation for how the same cancer-causing mutation can give rise to different types of brain...
Little Apparent Activity of Cetuximab in Refractory Metastatic Colorectal Cancer With KRAS G13D Mutation
Cetuximab (Erbitux) exhibited little apparent activity in refractory metastatic colorectal cancer harboring the KRAS G13D mutation, according to the findings of the phase II Australasian Gastro-Intestinal Trials Group ICECREAM study, which were reported by Segelov et al in the Journal of Clinical...
Spectrin Gene Identified as a Biomarker in HPV-Negative Oral Cavity Squamous Cell Carcinoma
Researchers have identified a gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue. Patients whose tumors express a gene called spectrin are 4.6 times more likely to die at any given time, according to a study by researchers at Loyola Medicine and Loyola...
Potential Targets for Loss of Appetite/Cachexia Related to Interleukin 18 Activity Identified in Early Studies
Loss of appetite during illness is a common and potentially debilitating phenomenon. In cancer patients especially, it can even shorten lifespan. Scientists at The Scripps Research Institute (TSRI) have discovered how an immune system molecule controls a brain circuit and reduces appetite. Their...
Trastuzumab/Lapatinib Active in Refractory, KRAS Codon 12/13 Wild-Type, HER2-Positive Metastatic Colorectal Cancer
Dual HER2 inhibition with trastuzumab (Herceptin) and lapatinib (Tykerb) was active in patients with refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer, according to an Italian phase II trial reported by Sartore-Bianchi et al in The Lancet Oncology. Study Details...
FDA Grants sBLA for Blinatumomab in Pediatric Patients With Ph–Negative Relapsed/Refractory B-Cell Precursor ALL
Amgen announced on May 3 that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric and adolescent patients with Philadelphia...
Effects of High Residential Segregation and Neighborhood Characteristics on Early-Stage NSCLC Surgery
Black residents of highly segregated neighborhoods were less likely to receive surgery for early-stage non–small cell lung cancer (NSCLC) than their peers in less-segregated neighborhoods, according to a study published by Johnson et al in Cancer Epidemiology, Biomarkers & Prevention....
ESTRO 2016: Radiotherapy vs Chemotherapy in a Study of Patients With Early Stage II Testicular Cancer
A large study of testicular cancer patients showed that radiation therapy was more effective than chemotherapy for patients with stage IIa disease (where one or more regional lymph nodes contain cancer cells, but they are less than 2 cm in diameter). These findings, presented at the ESTRO 35...
Study Finds Cancer Mortality Risks From Long-Term Exposure to Ambient Fine Particulate Matter
Long-term exposure to ambient fine particulate matter, a mixture of environmental pollutants, was associated with increased risk of mortality for many types of cancer in an elderly Hong Kong population, according to a study published by Wong et al in Cancer Epidemiology, Biomarkers &...
Tight Junction Protein 1 May Identify Sensitivity to Proteasome Inhibitors in Patients With Multiple Myeloma
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by researchers from The...
